Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kates, R. A.
690  Ergebnisse:
Personensuche X
?
1

Differential impact of prognostic parameters in hormone rec..:

Christgen, M. ; Harbeck, N. ; Gluz, O....
European Journal of Cancer.  138 (2020)  - p. S1 , 2020
Link: https://doi.org/10.1016/..
 
?
2

Strong impact of MammaPrint and BluePrint on treatment deci..:

WSG-PRIMe investigators in Germany, Austria, Switzerland ; Wuerstlein, R. ; Kates, R....
Breast Cancer Research and Treatment.  175 (2019)  2 - p. 389-399 , 2019
Link: https://doi.org/10.1007/..
 
?
3

ADAPTcycle – adjuvant dynamic marker-adjusted personalized ..:

Harbeck, N. ; Gluz, O. ; Christgen, M....
The Breast.  44 (2019)  - p. S133 , 2019
Link: https://doi.org/10.1016/..
 
?
4

Five-year results of the prospective Phase III WSG PlanB tr..:

Gluz, O. ; Nitz, U. ; Christgen, M....
The Breast.  32 (2017)  - p. S93 , 2017
Link: https://doi.org/10.1016/..
 
?
5

Impact of MammaPrint and BluePrint on early breast cancer t..:

Wuerstlein, R. ; Grischke, E.M. ; Gluz, O....
The Breast.  32 (2017)  - p. S107 , 2017
Link: https://doi.org/10.1016/..
 
?
6

Impact of guideline-based use of uPA/PAI-1 on patient outco..:

Kolben, Thomas ; Augustin, D. ; Armbrust, R....
Breast Cancer Research and Treatment.  155 (2015)  1 - p. 109-115 , 2015
Link: https://doi.org/10.1007/..
 
?
7

260 Primary Tumor in Breast Cancer and Its Phenotype in Pos..:

Wuerstlein, R. ; Freudenberger, M. ; Wildenburg, L....
European Journal of Cancer.  48 (2012)  - p. S118 , 2012
Link: https://doi.org/10.1016/..
 
?
8

PP 30 Prospective comparison of Recurrence Score, uPA/PAI-1..:

Wuerstlein, R. ; Gluz, O. ; Kreipe, H....
European Journal of Cancer.  47 (2011)  - p. S33-S34 , 2011
Link: https://doi.org/10.1016/..
 
?
9

P178 Prospective comparison of uPA/PAI-1, Ki-67 based molec..:

Liedtke, C. ; Gluz, O. ; Kreipe, H....
The Breast.  20 (2011)  - p. S38 , 2011
Link: https://doi.org/10.1016/..
 
?
10

PP11 Expression differences of proteolytic factors uPA, PAI..:

Dorn, J. ; Harbeck, N. ; Kates, R....
European Journal of Cancer Supplements.  7 (2009)  4 - p. 16-17 , 2009
Link: https://doi.org/10.1016/..
 
?
11

Results of the German IPEP study evaluating the tolerabilit..:

Warm, M. ; Thomas, A. ; Ziegler, K....
European Journal of Cancer Supplements.  6 (2008)  7 - p. 127 , 2008
Link: https://doi.org/10.1016/..
 
?
12

Challenging tumour aggressiveness – Individualising patient..:

Harbeck, N. ; Kates, R. ; Thomssen, C...
European Journal of Cancer Supplements.  6 (2008)  7 - p. 2-3 , 2008
Link: https://doi.org/10.1016/..
 
?
13

Hierarchical neural net technology for molecular staging wi..:

Kates, R. ; Allgayer, H. ; Harbeck, N.
European Journal of Cancer Supplements.  4 (2006)  6 - p. 9 , 2006
Link: https://doi.org/10.1016/..
 
?
14

ID: 117 Disease processes may be reflected by correlations ..:

Schmitt, M. ; Dorn, J. ; Kates, R....
Journal of Thrombosis and Haemostasis.  4 (2006)  s1 - p. 70-70 , 2006
Link: https://doi.org/10.1111/..
 
?
15

HER2 status and UPA/PAI-1 provide complementary information..:

Zemzoum, I. ; Kates, R. ; Schmitt, M....
The Breast.  12 (2003)  - p. S23-S24 , 2003
Link: https://doi.org/10.1016/..
 
1-15